Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Upstream Bio (NASDAQ:UPB – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares Lucid Diagnostics and Upstream Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucid Diagnostics | $4.71 million | 17.17 | -$58.01 million | ($0.47) | -0.85 |
| Upstream Bio | $2.85 million | 62.07 | -$143.44 million | ($2.90) | -1.11 |
Lucid Diagnostics has higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
74.0% of Lucid Diagnostics shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by insiders. Comparatively, 16.5% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Lucid Diagnostics and Upstream Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucid Diagnostics | -959.76% | N/A | -119.57% |
| Upstream Bio | -4,955.67% | -48.40% | -46.57% |
Volatility and Risk
Lucid Diagnostics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Upstream Bio has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Lucid Diagnostics and Upstream Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
| Upstream Bio | 1 | 2 | 4 | 0 | 2.43 |
Lucid Diagnostics currently has a consensus price target of $4.19, suggesting a potential upside of 952.14%. Upstream Bio has a consensus price target of $29.67, suggesting a potential upside of 818.47%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Lucid Diagnostics is more favorable than Upstream Bio.
Summary
Lucid Diagnostics beats Upstream Bio on 9 of the 13 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
About Upstream Bio
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
